Last reviewed · How we verify
RIPK1 inhibitor
RIPK1 inhibitor is a Small molecule drug developed by Sanofi. It is currently in Phase 1 development. Also known as: SAR443820.
A RIPK1 inhibitor, specifically SAR443122, is being studied in clinical trials for its potential effects on immune system responses in severe COVID-19, multiple sclerosis, and cutaneous lupus erythematosus. The mechanism of SAR443122 involves inhibition of the receptor-interacting protein kinase 1 (RIPK1), according to ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Sanofi is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | RIPK1 inhibitor |
|---|---|
| Also known as | SAR443820 |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 (PHASE1)
- Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (PHASE2)
- Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RIPK1 inhibitor CI brief — competitive landscape report
- RIPK1 inhibitor updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about RIPK1 inhibitor
What is RIPK1 inhibitor?
Who makes RIPK1 inhibitor?
Is RIPK1 inhibitor also known as anything else?
What development phase is RIPK1 inhibitor in?
Related
- Manufacturer: Sanofi — full pipeline
- Also known as: SAR443820
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing